Oral compromise in systemic sclerosis
Abstract
The gastrointestinal (GI) tract is affected in up to 90% of patients with Systemic Sclerosis (SS). The symptoms are varied according to the site and degree of commitment. Dysphagia, reflux, nausea, vomiting, abdominal pain, diarrhea, constipation, fecal incontinence, and weight loss are the most commonly reported symptoms. GI compromise severely affects quality of life and is one of the major causes of morbidity and mortality of the disease.References
I. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-205.
II. Clements PJ, Becvar R, Drosos AA, Ghattas L, Gabrielli A. Assessment of gastrointestinal involvement. Clin Exp Rheumatol. 2003;21(3 Suppl 29):S15-8.
III. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology. 2009;48(Supplement 3):iii36-iii39.
IV. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940-944.
V. Scolnik M, Lancioni E, Saucedo C, et al. Systemic sclerosis in Argentina: evaluation of a large cohort from a single centre and comparison with other international series. Clin Exp Rheumatol. 32(6 Suppl 86):S-94-7.
VI. V itali C, Borghi E, Napoletano A, et al. Oropharyngolaryngeal Disorders in Scleroderma: Development and Validation of the SLS Scale. Dysphagia. 2010;25(2):127-138.
VII. Scardina GA, Mazzullo M, Messina P. [Early diagnosis of progressive systemic sclerosis: the role of oro-facial phenomena]. Minerva Stomatol. 51(7-8):311-317.
VIII. Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal Manifestations of Systemic Sclerosis. Dig Dis Sci. 2008;53(5):1163-1174.
IX. C larke, John O; Hirano I. Scleroderma : From Pathogenesis to Comprehensive Management. First Edit. (Varga, John; Denton, Christopher P; Wigley FM, ed.). Springer; 2012.
X. Ramos-Casals M, Brito-Zerón P, Font J. The Overlap of Sjögren’s Syndrome with Other Systemic Autoimmune Diseases. Semin Arthritis Rheum. 2007;36(4):246-255.
XI. Avouac J, Sordet C, Depinay C, et al. Systemic sclerosis– associated Sjögren’s syndrome and relationship to the limited cutaneous subtype: Results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum. 2006;54(7):2243-2249.
XII. Nakamura T, Higashi S, Tomoda K, Tsukano M, Sugi K. Primary biliary cirrhosis (PBC)–CREST overlap syndrome with coexistence of Sjögren’s syndrome and thyroid dysfunction. Clin Rheumatol. 2007;26(4):596-600.
XIII. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-558.
Copyright (c) 2016 Argentine Journal of Rheumatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
